Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

The company’s shares closed yesterday at $29.89. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. According to ...

Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. In addition to Oppenheimer, 89bio also received a Hold from RBC ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...